Cambridge Healthtech Institute’s 3rd Annual
Emerging Immuno-Oncology Targets
Novel Targets and Pathways for Cancer Immunotherapy and Combinations
August 8-9, 2019
While cancer immunotherapy has made a giant leap in the past five years, the majority of therapies at advanced stages of development are clustered in a similar target space. The increased investment in immuno-oncology has created an urgent opportunity
to discover and populate new target spaces that either present new classes of immunotherapies or can be used in combination with existing products. Cambridge Healthtech Institute’s Third Annual Emerging Immuno-Oncology Targets conference will cover the
emerging target space, including immunomodulatory inhibitor and agonist targets, stromal and immune cell targets, and strategies for rational combination immunotherapy. Case studies of preclinical and translational approaches to the discovery and
validation of new immuno-oncology targets and combinations will be presented.
Understanding Immune Checkpoint TIM-3 Biology and Anti-TIM-3 Antibody for Cancer Immunotherapy
Xiaomo Jiang, PhD, Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research
Combining OX40 Agonists with TGFb and PD-1 Inhibitors
Andrew Weinberg, PhD, Chief, Laboratory of Basic Immunology, Providence Health & Services
Novel, High-Potency STING Agonists Regress Immunotherapy-Resistant Cancers
Michael A. Curran, PhD, Associate Professor, Immunology, Scientific Director, ORBIT Platform, The University of Texas MD Anderson Cancer Center
Coordinate Targeting of Innate and Adaptive Immunity for Cancer Immunotherapy
Jon Wigginton, MD, Senior Vice President, Clinical Development & CMO, MacroGenics
Development of TNF Superfamily Agonists
Andreas Raue, Director, Research, Merrimack Pharmaceuticals, Inc.
Cytokine Engineering for Immuno-Oncology Using Polymer Conjugation
Steve Doberstein, PhD, CSO & Senior Vice President, Research, Nektar Therapeutics
The TNFR2 Immuno-Oncology Target
Denise Faustman, MD, PhD, Associate Professor & Director, Immunobiology Lab, Massachusetts General Hospital, Harvard Medical School
Preliminary First-in-Human Data with a Novel MAB, NEO 201, Targeting a Novel Neoantigen in Solid Tumors
Philip Arlen, MD, President & CEO, Precision Biologics
How to Identify a Good Tumor Rejection Mediating Neoepitope
Pramod Srivastava, MD, PhD, Director, Carole and Ray Neag Comprehensive Cancer Center & Professor of Immunology and Medicine, University of Connecticut School of Medicine
Driving T Cell Responses to Neoantigens - the Importance of Priming and Accurate Target Selection
Andrew Allen, MD, PhD, President and CEO, Gritstone Oncology
Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics
and what they look for in a partner or investment.
Panelists: Michael Woo, MBA, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.
Kathryn McCabe, PhD, Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company
Scott M. DeWire, PhD, Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.
For more details on the conference, please contact:
Executive Director, Conferences
Cambridge Healthtech Institute
For partnering and sponsorship information, please contact:
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286